Synthetic, topically delivered innate immunomodulators
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
123
NCT05255822
INNA-051 Influenza Challenge Study
Phase: Phase 2
Role: Lead Sponsor
Start: Feb 28, 2022
Completion: Aug 23, 2022
NCT05118763
Intranasal INNA-051 for Prevention of COVID-19 in Adults
Start: Mar 1, 2022
Completion: Dec 31, 2022
Loading map...